Kiniksa (KNSA) expects its current operating plan to remain cash flow positive on an annual basis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa reports Q3 EPS 23c, consensus 37c
- Kiniksa Pharmaceuticals’ Promising Study on KPL-387 for Recurrent Pericarditis
- KNSA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Strong Commercial Execution and Growth Potential Drive Buy Rating for Kiniksa Pharmaceuticals
- Kiniksa announces Orphan Drug Designation for KPL-387